trial · primary record
SOMATROPINE* : Norditropine® simplexx®
Anorexia Nervosa
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2021-03 |
| Primary endpoint | the growth-velocity |
| Registry ID | NCT01626833 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:11.443Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01626833
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.